Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Lemery

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Nature Reviews. Clinical Oncology|February 9, 2022
Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyondSteven Lemery, Richard Pazdur
The New England Journal of Medicine|October 12, 2017
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the IndicationSteven Lemery, Patricia Keegan, Richard Pazdur
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Tissue-Agnostic Drug DevelopmentKeith T Flaherty, Dung T Le, Steven Lemery
Therapeutic Innovation & Regulatory Science|May 30, 2017
Ten-Year Experience for the Center for Drug Evaluation and Research, Part 2: FDA's Role in Ensuring Patient SafetyJonathan P Jarow, Steven Lemery, Kevin Bugin, et al.
Therapeutic Innovation & Regulatory Science|May 30, 2017
Overview of FDA's Expanded Access Program for Investigational DrugsJonathan P Jarow, Peter Lurie, Sarah Crowley Ikenberry, et al.
Therapeutic Innovation & Regulatory Science|December 6, 2016
Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year PeriodJonathan P Jarow, Steven Lemery, Kevin Bugin, et al.
The Lancet. Oncology|May 5, 2018
Anti-PD-1 antibody treatment for melanoma - Authors' replyJulia A Beaver, Patricia Keegan, Steven Lemery, et al.
Arthritis and Rheumatism|May 28, 2010
Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug AdministrationPeter Diak, Jeffrey Siegel, Lois La Grenade, et al.
Oncology (Williston Park, N.Y.)|August 29, 2009
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpuraFaranak Jamali, Steven Lemery, Kassa Ayalew, et al.
The Oncologist|June 23, 2016
Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung CancerDickran Kazandjian, Gideon M Blumenthal, Lola Luo, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Nature Reviews. Clinical Oncology|February 9, 2022
Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyondSteven Lemery, Richard Pazdur
The New England Journal of Medicine|October 12, 2017
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the IndicationSteven Lemery, Patricia Keegan, Richard Pazdur
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Tissue-Agnostic Drug DevelopmentKeith T Flaherty, Dung T Le, Steven Lemery
Therapeutic Innovation & Regulatory Science|May 30, 2017
Ten-Year Experience for the Center for Drug Evaluation and Research, Part 2: FDA's Role in Ensuring Patient SafetyJonathan P Jarow, Steven Lemery, Kevin Bugin, et al.
Therapeutic Innovation & Regulatory Science|May 30, 2017
Overview of FDA's Expanded Access Program for Investigational DrugsJonathan P Jarow, Peter Lurie, Sarah Crowley Ikenberry, et al.
Therapeutic Innovation & Regulatory Science|December 6, 2016
Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year PeriodJonathan P Jarow, Steven Lemery, Kevin Bugin, et al.
The Lancet. Oncology|May 5, 2018
Anti-PD-1 antibody treatment for melanoma - Authors' replyJulia A Beaver, Patricia Keegan, Steven Lemery, et al.
Arthritis and Rheumatism|May 28, 2010
Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug AdministrationPeter Diak, Jeffrey Siegel, Lois La Grenade, et al.
Oncology (Williston Park, N.Y.)|August 29, 2009
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpuraFaranak Jamali, Steven Lemery, Kassa Ayalew, et al.
The Oncologist|June 23, 2016
Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung CancerDickran Kazandjian, Gideon M Blumenthal, Lola Luo, et al.
Pageof 3